Cajal Neuroscience Inc. 
1150 Eastlake Ave E, Ste 600/700. 
Seattle, WA 98109.

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

LinkedIn

Twitter

Cajal is building a research and development team with the passion, drive, and scientific expertise to execute its bold mission of generating novel disease-altering therapies for neurodegeneration.

Our Team

Andrew is Co-Founder and Co-Chief Executive Officer at Cajal.

Prior to Cajal, Andrew was Senior Director of Business Development at Celgene, where he led the execution of Celgene’s cell therapy partnerships and transactions. He also held previous roles in Translational Medicine at Celgene, focused on leveraging novel single cell sequencing techniques for target discovery in oncology.

Throughout his industry career, Andrew has continued to practice as a clinical geneticist at the University of Washington Medical Center and brings this unique perspective to the challenge of understanding neurodegeneration. Andrew also serves on the Board of Directors of Life Science Washington.

Andrew received his MD and MBA degrees from Harvard Medical School and Harvard Business School, before completing his residency and fellowship at University of Washington in internal medicine and medical genetics. 

Ian is Co-Founder and Co-Chief Executive Officer at Cajal. 

Prior to Cajal, Ian was part of the founding team at Kallyope and was the Head of Platform Biology and Technology, where he built and led a highly integrated team of molecular biologists, neuroscientists, and data scientists in the discovery of new therapeutic targets that harness the gut-brain axis.

Ian is also a Venture Partner at Lux Capital, where he has been involved in the formation and early building of numerous companies (including Cajal and Kallyope).

Ian completed his PhD at Cold Spring Harbor Laboratory, where he developed novel tools for high throughput mapping of brain connectivity using DNA sequencing. These tools have served as the foundation for Cajal’s efforts on in vivo multiplexed assays.

Kimberly is Chief Development Officer at Cajal. Kimberly leads the strategy and execution of Cajal’s drug discovery pipeline across multiple modalities including small molecules, biologics, and ASOs.

Kimberly brings over 15 years of experience in drug development. Most recently, Kimberly was VP of Translational Sciences at Denali Therapeutics where she built and executed Denali’s biomarker-driven development strategy, enabling rigorous decision-making for more than 8 clinical-stage programs in Parkinson’s, Alzheimer’s, ALS, frontotemporal dementia, MS and lysosomal storage disorders. Previously, she served as Associate Director of Translational Neuroscience at Genentech. 

Kimberly has over 80 peer reviewed publications exploring disease-related neuroscience and the relationship between specific signaling events and complex changes in brain health and behavior. She received her PhD in neurobiology and behavior from Columbia University and a BA in cognitive science from Harvard University.

Leslie serves as General Counsel at Cajal, where she oversees Cajal’s intellectual property strategy and provides legal counsel across licensing and transactions, contracts, and general corporate matters.

Leslie has over 20 years of experience in the legal and biotech industries. She has managed extensive patent portfolios across a broad range of modalities and therapeutic areas, and has provided legal guidance for matters spanning early research to commercialization. Most recently, Leslie was VP of Intellectual Property and Legal Affairs at Neoleukin Therapeutics. She has held prior legal counsel and intellectual property roles at Seattle Genetics and the Infectious Disease Research Institute.

Since 2015, Leslie has also served as a volunteer mediator with the Dispute Resolution Center of King County. Leslie received a BS in Chemistry from Brown University and her JD from Columbia Law School.

Ben is Vice President of Computational Biology at Cajal. Ben leads a team of geneticists, computational biologists, and software engineers to employ advanced multi-omics methods to support Cajal’s target discovery and validation. Ben’s team is also responsible for building scalable data pipelines to process and analyze massive amounts of 3D imaging and sequencing data generated from Cajal’s platform.

Previously, Ben was Director of Neurodegenerative Research at Sage Bionetworks, where he led a team of researchers to integrate and analyze large-scale multi-omics data obtained from the AMP-AD (Accelerating Medicine Partnership - Alzheimer’s Disease) consortium. Ben also led Sage’s efforts in variant prioritization for generation of new mouse models of late onset Alzheimer’s disease and characterization of robust and reproducible transcriptomic signatures of disease. 

Ben started his career in research at the Fred Hutchinson Cancer Research Center and later the University of Washington, developing new computational methods to identify causal rare variants and disease drivers. Ben received a B.S. in biochemistry from Washington State University and completed his Ph.D. in computational biology from Cornell University.

Valerie is Vice President of Strategy and Corporate Development at Cajal. Valerie is responsible for leading business development, portfolio strategy, competitive intelligence, and investor relations efforts. 

Previously, Valerie was at ClearView Healthcare Partners, a life sciences strategy consulting firm that specializes in working with biotech and pharmaceutical companies. At ClearView, Valerie led engagements on corporate strategy, portfolio strategy, and business development, with a particular focus on neuroscience, rare diseases, and emerging technology platforms. She has also worked as an independent consultant for early-stage biotech companies and venture firms.

Valerie received her MBA degree from MIT Sloan School of Management and a BA in economics from Yale University.

Guy is Vice President of Chemistry at Cajal, where he leads the small molecule discovery chemistry efforts for the company.

Guy brings over 26 years of experience in drug discovery and development to Cajal. Guy has extensive CNS drug discovery experience as the former Head of Chemistry at Dart Neuroscience. At Dart, he oversaw the discovery of 6 clinical candidates for the treatment of various neurological disorders. Prior to Dart, Guy was Head of Pain Discovery Chemistry at Janssen Pharmaceuticals where he managed the discovery and development of 8 clinical candidates, including the company's FAAH inhibitor and P2X7 inhibitor programs for neuropsychiatric indications. Guy has also recently served as Vice President of Chemistry for Annexon Biosciences, developing small molecule complement inhibitors, Libra Therapeutics, developing small molecule autophagy modulators for neurodegeneration, and Convelo Therapeutics, developing remyelination therapeutics for multiple sclerosis.

Guy received his PhD in Chemistry from UC Riverside and completed postdoctoral studies at UC Berkeley in the area of natural product synthesis and synthetic methodology. He has over 100 peer reviewed publications and published patent applications, primarily in the areas of synthetic and medicinal chemistry.

Rob has over 25 years of experience as a physician, scientist, and entrepreneur. He is a Venture Partner at Frazier Life Sciences, where he co-founded and currently serves as the Chairman of the Board and Chief Executive Officer of HilleVax. 

Rob recently was Executive Vice President and Head of Business Development and Alliances at Celgene until the acquisition of Celgene by Bristol-Myers Squibb in 2019. Rob joined Celgene in 2014 to lead their efforts in immuno-oncology and was promoted to Executive Vice President and Chief Scientific Officer in 2016.

Prior to Celgene, Rob co-founded VentiRx Pharmaceuticals as an entrepreneur-in-residence at Frazier and served as President and Chief Executive Officer. He has also held roles as Chief Medical Officer of Dendreon and Vice President of Medical Genetics at Corixa (acquired by GlaxoSmithKline). Rob completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies.

Josh is co-founder and Managing Partner of Lux Capital, a venture capital firm that focuses on early-stage science and technology investments. Josh is a Director at Kallyope, Variant Bio, Gandeeva Therapeutics, and Strateos, and helped lead the firm’s investment in Resilience. Josh also serves as a Director at several other companies across the physical sciences and technology industries, including Shapeways, Varda, Kymeta, and Kurion. Before founding Lux Capital in 2000, Josh worked in investment banking at Salomon Smith Barney and in capital markets at Merril Lynch. 

Josh is a columnist with Forbes and Editor for the Forbes/Wolfe Emerging Tech Report. He has been invited to The White House and Capitol Hill to advise on nanotechnology and emerging technologies, and a lecturer at MIT, Harvard, Yale, Cornell, Columbia and NYU. He is a term member at The Council on Foreign Relations and Chairman of Coney Island Prep charter school, where he grew up in Brooklyn. Josh graduated from Cornell University with a B.S. in Economics and Finance.

Tim is a Managing Partner of The Column Group. Since joining the firm in 2007, Tim has contributed to the conception, formation, and management of more than a dozen portfolio companies. Tim serves on the board of Carmot Therapeutics, Surrozen, Neurona Therapeutics, Nura Bio, Kallyope, Plexium, and Synthekine. He was previously the founding CEO at Peloton Therapeutics and also served as Chairman of the Board of Directors of Nurix Therapeutics.

Prior to joining The Column Group, Tim was a scientist at KAI Pharmaceuticals, where he focused on the discovery and development of selective protein kinase C inhibitors. Before KAI, Tim worked at UC Berkeley as a graduate student and postdoc in the lab of Dr. Robert Tjian. Tim received his undergraduate degree from Stanford University and completed his Ph.D. and postdoc at UC Berkeley in the lab of Dr. Robert Tjian.

Jennifer Jarrett is an accomplished executive in the healthcare and technology industries. She currently serves as the COO of Arcus Biosciences where she is responsible for a variety of functions including finance, investor relations, program management, corporate development, alliance management, commercial, and medical affairs. 

Previously, she served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc. Prior to Arcus, Jennifer was Chief Financial Officer of Medivation, a commercial oncology company, which was acquired by Pfizer. Jennifer spent 20 years in investment banking, including an extensive tenure at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. 

Jennifer previously served on the boards of Radius Pharma, Syndax Pharmaceuticals and Arena Pharmaceuticals, all of which were acquired. She currently serves on the boards of Arcus Biosciences, Syndax Pharmaceuticals, Zura Bio and LifeMine Therapeutics.  

Jennifer received a BA in Economics from Dartmouth College and an MBA from Stanford Graduate School of Business.

Andrew received his MD and MBA degrees from Harvard Medical School and Harvard Business School, before completing his residency and fellowship at University of Washington in internal medicine and medical genetics.

Dr. Huda Zoghbi is Professor of Pediatrics, Molecular and Human Genetics, Neurology, and Neuroscience at Baylor College of Medicine, an Investigator with the Howard Hughes Medical Institute, and the founding Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital. 

Huda's interests range from neurodevelopment to neurodegeneration. Her discovery that Spinocerebellar Ataxia Type 1 (SCA1) is caused by expansion of a polyglutamine tract in the ATAXIN1 gene led to critical advances in understanding disease mechanisms and potential therapeutic interventions for SCA1. Her subsequent findings, that such expansion of the mutant protein leads to neuronal dysfunction and death, have had profound implications on other diseases, including in late-onset neurodegenerative diseases that involve similar accumulation of disease-associated proteins. Huda's work in neurodevelopment also led to the discovery that mutations in MECP2 cause the postnatal neurological disorder Rett syndrome.

Huda has been widely recognized for her contributions to neuroscience and neurological diseases. She has been elected to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Her honors include the Kavli Prize in Neuroscience, the Brain Prize, the Breakthrough Prize in Life Sciences, the Canada Gairdner International Award, the Shaw Prize in Life Science and Medicine, and the Pearl Meister Greengard Prize from Rockefeller University, among numerous others. 

Dr. Anthony Zador is the Alle Davis Harris Professor of Biology and Chair of Neuroscience at Cold Spring Harbor Laboratory in New York. 

The goal of Anthony's research is to understand how brain circuitry gives rise to complex behavior. His laboratory has developed a revolutionary new approach to map the connectivity of the mouse brain at single-resolution (the “connectome”) using high throughput DNA sequencing. His laboratory has also pioneered the use of rodents in complex sensory decision tasks, to help understand the neural circuits underlying cortical processing and how that is disrupted in diseases such as autism.

Anthony is founder of the annual Computational and Systems Neuroscience (COSYNE) meeting, which now draws over 900 participants. He has been named a Gill Symposium Transformative Investigator for his work on sequencing-based brain mapping, and previously received an NIH Transformative Research Award, granted to “exceptionally innovative and unconventional research projects.”. He has also been recognized as one of the “Top 100 Leading Global Thinkers “ in Foreign Policy for his contributions to neuroscience. 

Dr. Charles Zuker is a Professor of Biochemistry; Professor of Molecular Biophysics; and Professor of Neuroscience in the College of Physicians and Surgeons at Columbia University. He is also a Howard Hughes Medical Institute Investigator (HHMI) and spent six years as a Senior Fellow at the HHMI Janelia Farm Research Campus. 

Charles studies how the brain represents our sensory experiences and how it transforms reception into perception. Charles and his lab have integrated molecular biology, genetics, and physiology to study the biology of photoreception, mechanoreception, and more recently taste reception. His lab has discovered mammalian taste receptors for the five tastes (sweet, sour, bitter, salt, and “umami”), and made significant advances in the understanding of sight and hearing.

Charles has received numerous awards for his work, including an Alfred P. Sloan Foundation Fellowship, the W. Alden Spencer Award, the Cogan Award, and the International Flavor and Fragrances Award. He is a member of the National Academy of Sciences and the Institute of Medicine of the National Academies in addition to his American Academy of Arts and Sciences Membership. 

Dr. Richard Hargreaves is Senior Vice President and Head of Neuroscience Research and Early Development at Bristol Myers Squibb. 

In his current role, Richard is responsible for building and expanding Bristol Myers Squibb’s neuroscience pipeline, collaborating with biotech and academic partners across the neuroscience field, and partnering with key advocacy organizations. Prior to Bristol Myers Squibb, Richard was Corporate Vice President and Head of Neuroscience and Imaging Research at Celgene, and held senior scientific leadership positions in neuroscience research and development at both Biogen and Merck. 

Richard has led teams that have advanced numerous novel CNS PET imaging agents and contributed to the successful registration of numerous drug candidates across neuroscience, including Maxalt® for migraine, Belsomra® for insomnia, Ajovy® for prevention of migraine, Ubrelvy® for acute migraine, and Zeposia® for relapsing multiple sclerosis. 

Richard is a board member for Target ALS and on the scientific advisory board for the Silverstein Parkinson’s Disease Foundation. He has published >200 journal articles and been recognized by awards from the American Society for Clinical Pharmacology and Therapeutics for his work on CNS discovery imaging and the British Pharmacological Society.

Dr. David Holtzman is currently Professor of Neurology, Scientific Director of the Hope Center for Neurological Disorders, and Associate Director of the Knight Alzheimer’s Disease Research Center at Washington University in St. Louis.

David and his lab have made foundational contributions to understanding the cellular and molecular mechanisms of Alzheimer’s disease. His work has focused on studying Aβ metabolism and how it is regulated by synaptic activity, sleep, and other factors. He has also extensively studied the role of tau in Alzheimer’s disease and how ApoE, TREM2, and microglia impact tau-mediated neurodegeneration. David has been deeply involved in the development of biomarkers for Alzheimer’s disease and the advancement of numerous drug candidates for Alzheimer’s disease targeting Aβ, tau, and ApoE.

David's honors include the Potamkin Prize, the MetLife Award, the Rainwater Prize, and from Washington University, the Chancellor’s Award for Innovation and Entrepreneurship and the Carl and Gerty Cori Award. David has previously served as President of the American Neurological Association, and he has been elected to the AAAS as a Fellow, the National Academy of Medicine, the National Academy of Inventors, and the National Advisory Council of the NINDS and NIA.

Niranjan Bose is the Managing Director of Health & Life Sciences at Gates Ventures, where he serves as the Science Advisor to Mr. Bill Gates.

Prior to this, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. During his time with the Global Health Program, Bose was responsible for managing a portfolio of investments, which included clinical development of enteric vaccines (rotavirus, cholera, enterotoxigenic E. coli and shigella).

Niranjan holds a Ph.D. in biochemistry from Dartmouth College and an MS in biological sciences and BS in pharmaceutical sciences from Birla Institute of Technology and Science, Pilani, India. He also received the Business Bridge Diploma from the Tuck School of Business at Dartmouth.

Dr. Martin Burke is the May and Ving Lee Professor for Chemical Innovation at the University of Illinois at Urbana-Champaign. He is the founding Director of the Molecule Maker Lab and co-Founder of the Molecule Maker Lab Institute at UIUC. He also helped launch the Carle Illinois College of Medicine, serving as its inaugural Associate Dean for Research.

Martin's lab pioneered the development of molecular prosthetics for neurodegeneration, anemia, cystic fibrosis and other difficult to treat diseases caused by loss of protein function. His group also illuminated how the inherent robustness of living systems can interface with imperfect molecular prosthetics to restore physiology. These advances were driven by his lab’s iterative lego-like platform for small molecule synthesis. This new modular brand of organic chemistry has been automated and used by hundreds of labs worldwide to produce many different natural products, pharmaceuticals and materials. It has also been coupled to artificial intelligence to enable closed-loop discovery of a wide range of new molecular functions and is beginning to democratize molecular innovation.

Martin is a scientific founder of four biotechnology companies which have yielded six drug candidates in clinical trials. He is an elected member of the National Academy of Medicine and American Society for Clinical Investigation, a Fellow of the American Association for the Advancement of Science. He is also a winner of the ACS Cope Scholar Award, Hirata Gold Medal, Mukaiyama Award, and Nobel Laureate Signature Award for Graduate Education in Chemistry.

Dr. Andrew Singleton received his B.Sc. from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK. His research initially focused on genetic determinants of Alzheimer’s disease and dementia with Lewy bodies. His postdoctoral studies were spent at the Mayo Clinic in Jacksonville Florida. Andrew moved to the National Institute on Aging at NIH in 2001, becoming a principal investigator in 2002. In 2007 Andrew became a tenured senior investigator, in 2008 he became the Chief of the Laboratory of Neurogenetics, and in 2016 he was named an NIH Distinguished Investigator. In 2021 Andrew was named the Director of the new Center for Alzheimer’s and Related Dementias at NIH.

Andrew has published more than 700 articles on a wide variety of topics. His group works on the genetic basis of neurodegenerative disorders. The goal of this research is to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the molecular processes underlying disease.

Andrew currently is a member of numerous scientific advisory and editorials boards. Andrew was awarded the Boehringer Mannheim Research Award in 2005, the NIH Director’s Award in 2008 and again in 2016, and the Annemarie Opprecht Award for Parkinson’s disease research in 2008. In 2012 he became the first person to win the Jay van Andel Award for Outstanding Achievement in Parkinson’s Disease Research. In 2017 Andrew was awarded the American Academy of Neurology Movement Disorders Award and an Honorary Doctorate from his alma mater, the University of Sunderland. In 2019 Andrew was awarded the Robert A. Pritzker Prize for Leadership in Parkinson’s Research. In 2024 Andrew was a recipient of the Breakthrough Prize for Life Sciences.

We are proud to be backed by a set of world-class investors

A passionate team of scientists.

Leadership Team

Andrew Dervan, MD, MBA

Co-Founder and Co-Chief Executive Officer

Ian Peikon, PhD

Co-Founder and Co-Chief Executive Officer

Kimberly Scearce-Levie, PhD

Chief Development Officer

Leslie Aberman, JD

General Counsel

Ben Logsdon, PhD

Vice President, Computational Biology

Valerie Huang, MBA

Vice President, Strategy & Corporate Development

J. Guy Breitenbucher, PhD

Vice President, Chemistry

Team

Aaron Williams

Drug Discovery

Angelique Nelson

In Vitro Screens

Anna Frolova

Finance

Anna Josephson-Day

Facilities, EHS & Operations

Anna Minkina

Computational Biology

Arvis Sulovari

Computational Biology

Christian Gaetano

Engineering

David Paterson

Drug Discovery

Drew Friedmann

High Throughput Imaging

Fen Huang

Drug Discovery

Ignas Cerniauskas

Target Validation

Jen Whitesell

Translational Models

Jeremy Capalungan

Drug Discovery

Johnny Goforth

Target Validation

Karla Hirokawa

Translational Models

Kat Korvas

In Vivo Sciences

Kayla Hardwick

Computational Biology

Khleo Isaguirre

Lab & Operations

Luke Funk

In Vitro Screens

Madison Baird

Viral Tools

Mei Xu

Drug Discovery

Molly Lindbo

In Vivo Sciences

Nicole Sanford

Drug Discovery

Nile Graddis

Engineering

Ray Carrillo

In Vitro Pharmacology & Biomarkers

Scott Shaffer

Drug Discovery

Thuc Nguyen

Target Validation

Ya-Lin Lu

In Vitro Screens

Board of Directors

Rob Hershberg, MD, PhD

Co-Founder and Executive Chairman, Cajal Neuroscience

Josh Wolfe

Co-Founder and Managing Partner, Lux Capital

Tim Kutzkey, PhD

Managing Partner, The Column Group